“The
Oncologist” e-newsletter appeared in my in-box today. All useful background
information…
 |
Practice-Changing Article
This study shows
that women with gynecological cancer have problems related to work and
sexual dysfunction, even 5 years after diagnosis. The results of this
study will help improve clinicians’ awareness of the factors affecting
the lives of gynecological cancer survivors, even long after diagnosis
and treatment. They will also highlight for clinicians the areas that
are of importance to gynecological cancer survivors, making it possible
to guide management of these patients with a view to preventing
deteriorated health‐related quality of life after treatment. For the
health authorities, the results of this study underline that more than 5
years after gynecological cancer, the initial stage of disease no
longer affects quality of life, but there is a clear need for actions
targeting socio‐professional reintegration of survivors.
|
|
|
|
|
|
|
|
|
|
Review Article
The combination of dabrafenib plus trametinib has demonstrated substantial clinical activity in patients with BRAF
V600E‐mutant non‐small cell lung cancer, leading to U.S. Food and Drug
Administration approval. Although the combination has a manageable
safety profile, many toxicities associated with the regimen may not be
familiar to thoracic specialists or general oncologists. Extensive
clinical experience with the combination in patients with metastatic
melanoma has provided a wealth of strategies to identify and manage
adverse events associated with dabrafenib plus trametinib. These can be
used by medical oncologists to enhance early recognition of toxicities
and facilitate effective management, thereby improving quality of
treatment for patients.
|
|
|
|
|
|
|
Lessons Learned
> A shortened infusion of ramucirumab (from 60 to 20 minutes) was safe and feasible without infusion‐related reactions.
>
Twenty‐minute infusions of ramucirumab can be an option for patients
with no infusion‐related reactions during the first 60‐minute treatment.
|
|
|
|
|
|
|
Don't miss out on CME credits. These activities are expiring soon.
This
large prospective analysis showed that high tumor TS levels were
associated with improved DFS and OS following adjuvant therapy for colon
cancer, although tumor TS expression did not predict benefit of
5-FU-based chemotherapy.
|
The
study objective was to determine if there had been an improvement in
the patterns of use, storage, and disposal of opioids among cancer
outpatients following the implementation of a patient educational
program.
|
|
No comments:
Post a Comment